Genentech announced today that it received FDA approval for its Susvimo injection for treating macular degeneration (AMD).
South San Francisco-based Genentech, a member of the Roche Group, designed its Susvimo ranibizumab injection (100 mg/mL) for intravitreal use via ocular implant for treating people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Get the full story at our sister site, Drug Delivery Business News.